Health In Tech Earnings Call Highlights Rapid Scaling

Health In Tech, Inc. Class A ((HIT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Health In Tech, Inc. Class A’s latest earnings call struck a decidedly upbeat tone, with management underscoring rapid revenue growth, expanding margins, and positive cash generation for 2025. Executives acknowledged softer fourth‑quarter profitability and lingering seasonality, but argued that product momentum and disciplined investment set up the business for stronger scaling into 2026.

Surging Full-Year Revenue Underlines Platform Adoption

Total revenue for 2025 climbed 71% year over year to $33.3 million, signaling strong demand for Health In Tech’s AI‑enabled underwriting marketplace. Management framed this growth as broad‑based, pointing to expanding usage across its broker and third‑party administrator network and higher conversion of quotes into funded cases.

Quarterly Growth Remains Strong Despite Seasonality

Fourth‑quarter revenue rose 53% from the prior year to $7.5 million, confirming that momentum carried into year‑end even as renewal cycles created timing noise. The company stressed that quarter‑to‑quarter variability is inherent to the employer benefits calendar, and that investors should focus on the robust full‑year trajectory.

Profitability Improves As Operating Leverage Kicks In

For the full year, adjusted EBITDA reached $4.1 million, or roughly 12.3% of revenue, an 81% jump that highlights increasing operating leverage. GAAP net income nearly doubled to $1.2 million, around 4% of revenue, reinforcing the narrative that scale is gradually translating into healthier margins.

Distribution and Enrollment Build the Growth Engine

Health In Tech expanded its distribution network by about 34% to roughly 885 brokers, TPAs, and agency partners, giving the marketplace a wider reach. Enrolled employees increased 23% to 22,515, which management linked to higher quoting activity and better conversion efficiency across the platform.

Upmarket Push Targets Larger Employers

The company reported meaningful product‑market progress with an upmarket move, expanding its EDIBS platform to serve employers with more than 100 workers. It also compressed underwriting timelines for these larger groups from about three months to roughly two weeks, a change designed to boost broker productivity and placement rates.

Guidance Signals Confident Path to Further Scale

Management introduced 2026 revenue guidance of $45 million to $50 million, implying 35% to 50% growth over 2025 levels and reinforcing confidence in near‑term scaling. They attributed this outlook to the enlarged distribution base, rising enrollment, and product enhancements that can shrink time‑to‑revenue from years to just a few quarters.

Solid Cash Generation and Balance Sheet Investments

Operating cash flow turned positive at $3.1 million for 2025, giving the company more flexibility to fund growth. Health In Tech also tightened working capital, cutting days sales outstanding from 29 to 14, invested $3.2 million in platform development, and closed the year with $7.7 million in cash and equivalents.

Platform Enhancements Deepen Competitive Moat

In January 2026, the firm launched more than 100 preconfigured stop‑loss programs, expanding options for self‑funded employers and their advisors. Management highlighted ongoing AI investments, a beta combining physiological and claims data, and strengthened cloud partnerships as core enablers of marketplace expansion.

Fourth-Quarter Profitability Takes a Step Back

Despite strong top‑line growth, fourth‑quarter adjusted EBITDA slipped to $300,000 from $500,000 a year earlier, and GAAP net income came in at a $300,000 loss. The company cited planned reinvestment and timing factors behind a pre‑tax loss of $400,000, arguing these pressures were temporary and tied to growth initiatives.

Seasonality and Timing Volatility Remain a Feature

Management repeatedly warned that employer renewal cycles do not line up neatly with calendar quarters, leading to uneven quarterly results. Fourth‑quarter performance reflected this seasonality as well as stepped‑up spending on go‑to‑market, broker engagement, and new product launches that are expected to pay off in later periods.

Large-Employer and Rate-Stabilization Efforts Still Nascent

The company’s push into large‑group underwriting and a three‑year rate stabilization program remains in early stages, with long sales cycles and limited current revenue impact. Management expects these efforts to become more meaningful later in 2026, especially as many municipal renewals cluster around January and July effective dates.

Operating Expenses High But Trending in the Right Direction

Total operating expenses reached $19.4 million, about 58% of revenue, which management acknowledged is still elevated for a scaling platform. However, the ratio improved 16% year over year, and executives emphasized that current spending levels reflect deliberate investment to capture market share and enhance the technology stack.

Prescription-Cost Strategy Clouded by Policy Uncertainty

While Health In Tech maintains partnerships that touch prescription‑benefit management, management described the drug‑cost landscape as unsettled. They pointed to potential government intervention and broader industry changes as reasons to remain cautious, suggesting that prescription management is not a near‑term strategic pillar.

Early-Stage Scale Against a Massive Market

Executives underscored how early the company is relative to its market opportunity, noting roughly 1.1 million brokers nationwide and penetration well below 0.1%. With the platform still representing only a small slice of an estimated $0.9 trillion self‑funded market, leadership highlighted both the sizable runway and the execution risk inherent in scaling.

Confident Guidance Anchors Forward-Looking Story

Looking ahead, management’s 2026 revenue guidance of $45 million to $50 million rests on continued distribution growth, faster implementation cycles, and a richer product suite, including new stop‑loss configurations. They backed this outlook with 2025 profitability metrics, positive cash flow, leaner receivables, and a solid cash position, while acknowledging that short‑term quarterly volatility will likely persist as they reinvest for growth.

Health In Tech’s earnings call painted a picture of a company successfully scaling an AI‑driven insurance marketplace while navigating the usual growing pains of reinvestment and seasonality. For investors, the key takeaways are rapid top‑line growth, improving profitability, and a still‑early position in a large self‑funded benefits market, balanced by execution risk and near‑term earnings volatility.